Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
Superinvestors holding RGEN, Q2 2026
3 superinvestors report holding Repligen Corp on Form 13F, worth $286.9M in total. Weight is Repligen Corp's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Maverick CapitalLee Ainslie | 2.4% | 1,984,554 | $270.8M | Added+30.7% |
| Duquesne Family OfficeStanley Druckenmiller | 0.2% | 77,400 | $10.6M | New |
| Weitz Investment ManagementWally Weitz | 0.4% | 40,800 | $5.57M | Added+60.0% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of RGEN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
3 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Added
- Maverick Capital (+30.7%), Weitz Investment Management (+60.0%)
Q1 2026
2 superinvestors holding at quarter end
Q2 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital